Target intelligence / Profile preview

ARV1 fatty acid homeostasis modulator (ARV1)

Target
ARV1
Molecular classification
Transmembrane protein, Lipid transporter, Putative lipid scramblase, Other (no evidence supports classical receptor, enzyme, or ion channel functions)
01

Overview

ARV1 fatty acid homeostasis modulator (ARV1) is a conserved transmembrane protein containing a zinc ribbon motif at the N-terminus. It is believed to act as a lipid transporter or scramblase within the endoplasmic reticulum, regulating cholesterol and fatty acid homeostasis, as well as the asymmetry and trafficking of membrane lipids. ARV1 plays roles in glycosyl-phosphatidylinositol anchor biosynthesis, cellular stress response (especially unfolded protein response), and is essential for proper metabolic function. Loss-of-function mutations in ARV1 are associated with severe neurodevelopmental disorders such as early infantile epileptic encephalopathy (DEE38/EIEE38), and studies in animal models indicate influence over obesity, insulin sensitivity, and cholesterol metabolism. No drugs are known to directly target ARV1, but its role in fundamental lipid metabolism and neurological health positions it as a potential target for future investigation.

Other names
ARV1Protein ARV1ARV1 homologHT035hARV1DEE38EIEE38
02

Mechanism of action

Not applicable; no direct pharmacological modulators yet identified

03

Biological functions

Regulation of cholesterol metabolic processRegulation of intracellular cholesterol transportFatty acid homeostasisGlycosyl-phosphatidylinositol (GPI) anchor biosynthesisCellular membrane lipid asymmetryModulation of unfolded protein response (UPR)
04

Disease associations

Epileptic encephalopathy (DEE38/EIEE38)Neurological defects (seizure, cerebellar ataxia, intellectual disability)Obesity and metabolic syndrome (animal models)Insulin sensitivity and glucose toleranceLipid metabolism disordersPotential roles in neurodegenerative diseases (speculative, based on cholesterol handling in neurons)
05

Safety considerations

Loss-of-function associated with epilepsy, seizures, neurological decline, metabolic dysregulation, and decreased survival in murine modelsChallenges may include risks of neurodevelopmental defects, unintended metabolic disruption
06

Interacting drugs

None established (No drugs directly target ARV1—studies involve knockouts or genetic modulation)
07

Biomarkers

Reduced levels of GPI-anchored proteins (e.g., CD16, CD66b, CD55, CD59, FLAER, CD73, CD109, CD87)Clinical mutations tracked in DEE38/EIEE38

Beyond the preview

Go deeper on ARV1 fatty acid homeostasis modulator (ARV1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARV1 fatty acid homeostasis modulator (ARV1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call